These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 27720403)

  • 21. Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers.
    Sharifi N; Amani R; Hajiani E; Cheraghian B
    Exp Biol Med (Maywood); 2016 Apr; 241(8):830-8. PubMed ID: 26811103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial.
    Asemi Z; Tabassi Z; Heidarzadeh Z; Khorammian H; Sabihi SS; Samimi M
    Pak J Biol Sci; 2012 Apr; 15(7):316-24. PubMed ID: 24163957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults.
    Pittas AG; Harris SS; Stark PC; Dawson-Hughes B
    Diabetes Care; 2007 Apr; 30(4):980-6. PubMed ID: 17277040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
    Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnesium-zinc-calcium-vitamin D co-supplementation improves glycemic control and markers of cardiometabolic risk in gestational diabetes: a randomized, double-blind, placebo-controlled trial.
    Karamali M; Bahramimoghadam S; Sharifzadeh F; Asemi Z
    Appl Physiol Nutr Metab; 2018 Jun; 43(6):565-570. PubMed ID: 29316405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium plus vitamin D3 supplementation facilitated fat loss in overweight and obese college students with very-low calcium consumption: a randomized controlled trial.
    Zhu W; Cai D; Wang Y; Lin N; Hu Q; Qi Y; Ma S; Amarasekara S
    Nutr J; 2013 Jan; 12():8. PubMed ID: 23297844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of vitamin D supplementation on metabolic profiles and liver function in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Tabrizi R; Moosazadeh M; Lankarani KB; Akbari M; Heydari ST; Kolahdooz F; Samimi M; Asemi Z
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S975-S982. PubMed ID: 28751149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial.
    Ebrahimpour-Koujan S; Sohrabpour AA; Giovannucci E; Vatannejad A; Esmaillzadeh A
    Nutr J; 2024 Feb; 23(1):24. PubMed ID: 38413933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Guo XF; Wang C; Yang T; Li S; Li KL; Li D
    Food Funct; 2020 Sep; 11(9):7389-7399. PubMed ID: 32966467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial.
    Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K
    Trials; 2018 Nov; 19(1):634. PubMed ID: 30445988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial.
    Asemi Z; Khorrami-Rad A; Alizadeh SA; Shakeri H; Esmaillzadeh A
    Clin Nutr; 2014 Apr; 33(2):198-203. PubMed ID: 23786900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial.
    Amanat S; Eftekhari MH; Fararouei M; Bagheri Lankarani K; Massoumi SJ
    Clin Nutr; 2018 Aug; 37(4):1210-1215. PubMed ID: 28647291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized-controlled clinical trial investigating the effect of omega-3 fatty acids and vitamin E co-supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes.
    Taghizadeh M; Jamilian M; Mazloomi M; Sanami M; Asemi Z
    J Clin Lipidol; 2016; 10(2):386-93. PubMed ID: 27055970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD.
    Asemi Z; Raygan F; Bahmani F; Rezavandi Z; Talari HR; Rafiee M; Poladchang S; Darooghegi Mofrad M; Taheri S; Mohammadi AA; Esmaillzadeh A
    Br J Nutr; 2016 Jul; 116(2):286-93. PubMed ID: 27198036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial.
    Razavi Zade M; Telkabadi MH; Bahmani F; Salehi B; Farshbaf S; Asemi Z
    Liver Int; 2016 Apr; 36(4):563-71. PubMed ID: 26503843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.
    Jamilian M; Maktabi M; Asemi Z
    Arch Iran Med; 2017 Oct; 20(10):640-645. PubMed ID: 29137465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Abolfathi M; Mohd-Yusof BN; Hanipah ZN; Mohd Redzwan S; Yusof LM; Khosroshahi MZ
    Complement Ther Med; 2020 Jan; 48():102273. PubMed ID: 31987257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Mirhafez SR; Farimani AR; Dehhabe M; Bidkhori M; Hariri M; Ghouchani BF; Abdollahi F
    J Gastrointestin Liver Dis; 2019 Jun; 28():183-189. PubMed ID: 31204416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.